JACC
HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
 QUICK SEARCH:   [advanced]


     


J Am Coll Cardiol, 2007; 49:1589-1599, doi:10.1016/j.jacc.2006.12.045 (Published online 30 March 2007).
© 2007 by the American College of Cardiology Foundation
This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
j.jacc.2006.12.045v1
49/15/1589    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (4)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Miller, D. T.
Right arrow Articles by Kwiatkowski, D. J.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Miller, D. T.
Right arrow Articles by Kwiatkowski, D. J.

CARDIOVASCULAR GENOMIC MEDICINE

Atherosclerosis

The Path From Genomics to Therapeutics

David T. Miller, MD, PhD*,§,1, Paul M. Ridker, MD, MPH, FACC{dagger},{ddagger},§,2, Peter Libby, MD, FACC{ddagger},§,* and David J. Kwiatkowski, MD, PhD*,§

* Division of Hematology, Brigham and Women’s Hospital, Boston, Massachusetts
{dagger} Division of Preventive Medicine and Center for Cardiovascular Disease Prevention, Brigham and Women’s Hospital, Boston, Massachusetts
{ddagger} Division of Cardiovascular Medicine, Brigham and Women’s Hospital, Boston, Massachusetts
§ Donald W. Reynolds Cardiovascular Clinical Research Center on Atherosclerosis at Brigham and Women’s Hospital and the Harvard Medical School, Boston, Massachusetts.

Manuscript received June 6, 2006; revised manuscript received October 30, 2006, accepted December 4, 2006.

* Reprint requests and correspondence: Dr. Peter Libby, Donald W. Reynolds Cardiovascular Clinical Research Center, Cardiovascular Medicine, Brigham and Women’s Hospital, Mallinckrodt Professor of Medicine, Harvard Medical School, 77 Avenue Louis Pasteur, NRB 7, Boston, Massachusetts 02115. (Email: plibby{at}rics.bwh.harvard.edu).

Recent rapid advances in genomic tools and techniques hold great promise for transforming the practice of cardiovascular medicine. Resources including the Human Genome Project and the International HapMap project, major technological advances in high-throughput genotyping and methods of statistical analysis, and methods for high-throughput gene expression and small molecule profiling allow researchers to confront issues that will fundamentally change the practice of cardiovascular medicine during the 21st century. Genomic, proteomic, and metabolomic studies of complex cardiovascular diseases such as atherosclerosis will bridge epidemiology and basic biology, and promise increased understanding of cardiovascular disease processes. Genetic approaches applied to atherosclerosis will continue to identify genes and pathways involved in the predisposition to and pathophysiology of atherosclerosis. Gene expression profiling refines our understanding of the dynamic nature of the atherosclerotic vascular wall and promises discovery and validation of targets for therapeutic intervention. Opportunities to translate genetic, genomic, proteomic, and metabolomic information into cardiovascular clinical practice have never been greater, but their fruition requires validation in large independent cohorts, achieved only through collaborative effort. Their continued success will depend on ongoing cooperation within the cardiovascular research community.

Abbreviations and Acronyms
  ALOX5AP = 5-lipoxygenase activating protein gene
  CAD = coronary artery disease
  CRP = C-reactive protein
  FLAP = 5-lipoxygenase activating protein
  HMG-CoA = 5-hydroxy-3-methylglutaryl-coenzyme A
  HSP27 = heat shock protein-27
  LDL = low-density lipoprotein
  LTA4H = leukotriene A4 hydrolase gene
  LTB4 = leukotriene B4
  MI = myocardial infarction
  MMP = matrix metalloproteinase
  OR = odds ratio
  Osm = oncostatin M
  Osmr = oncostatin M receptor
  PCSK9 = proprotein convertase subtilisin/kexin type 9 serine protease
  SNP = single nucleotide polymorphism
  TNFSF4 = tumor necrosis factor (ligand) superfamily, member 4




This article has been cited by other articles:


Home page
J Am Coll CardiolHome page
S. B. Damani and E. J. Topol
Future Use of Genomics in Coronary Artery Disease
J. Am. Coll. Cardiol., November 13, 2007; 50(20): 1933 - 1940.
[Abstract] [Full Text] [PDF]




HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
Copyright © 2007 by the American College of Cardiology Foundation.